What is the use of Dexamethasone (a corticosteroid) in Ear, Nose, and Throat (ENT) practice?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 26, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Dexamethasone is a widely used corticosteroid in ENT practice, particularly for its potent anti-inflammatory and anti-edema effects, and its use is supported by recent guidelines, such as those published in 2019 1.

Uses of Dexamethasone in ENT Practice

  • For acute sinusitis, dexamethasone can be prescribed as a short course of 0.5-1 mg daily for 5-7 days alongside antibiotics to reduce mucosal inflammation and improve drainage.
  • In cases of severe allergic rhinitis, a single dose of 8-12 mg intramuscularly can provide rapid relief of symptoms.
  • For post-tonsillectomy pain management, dexamethasone 0.15-0.5 mg/kg (maximum 10 mg) as a single intravenous dose during surgery significantly reduces pain, nausea, and vomiting.
  • In the management of sudden sensorineural hearing loss, a common regimen includes oral dexamethasone 10 mg daily for 7-14 days, with gradual tapering, or intratympanic injections of 4 mg/ml when systemic therapy is contraindicated, as supported by recent studies 1.
  • For laryngeal edema or croup, dexamethasone 0.6 mg/kg (maximum 16 mg) as a single oral or intramuscular dose is effective.

Mechanism of Action

Dexamethasone works by suppressing inflammatory mediators, reducing capillary permeability, and inhibiting prostaglandin synthesis, which explains its effectiveness in reducing inflammation and edema in ENT tissues.

Side Effects

Side effects are minimal with short-term use but can include hyperglycemia, mood changes, and increased susceptibility to infection with prolonged administration, as noted in several studies 1.

Recent Guidelines and Studies

Recent guidelines and studies, such as those published in 2019 1, support the use of dexamethasone in ENT practice, particularly for the management of sudden sensorineural hearing loss and other conditions. However, the use of dexamethasone should be individualized and based on the specific condition being treated, as well as the patient's medical history and other factors.

From the Research

Use of Dexamethasone in ENT Practice

  • Dexamethasone, a corticosteroid, is used in the treatment of sudden sensorineural hearing loss (SSNHL) in Ear, Nose, and Throat (ENT) practice 2, 3, 4, 5, 6.
  • The medication can be administered through intratympanic injection, where it is injected directly into the middle ear space through the tympanic membrane 2, 3, 4, 5.
  • Studies have shown that intratympanic dexamethasone can be beneficial in treating patients with SSNHL, with significant improvement in pure-tone averages (PTA) and hearing recovery rates 2, 3, 4, 5.
  • Systemic high-dose dexamethasone therapy has also been found to be effective in treating SSNHL, with a high percentage of patients showing functionally relevant recovery of hearing 6.

Efficacy of Dexamethasone

  • The efficacy of dexamethasone in treating SSNHL has been compared to other corticosteroids, such as methylprednisolone and triamcinolone, with no significant difference found in the effect between dexamethasone and these medications 3, 5.
  • The response rate to treatment with intratympanic dexamethasone has been reported to be around 70-80% 4, 5.
  • Factors that can affect the efficacy of dexamethasone in treating SSNHL include the duration of symptoms, presence of vertigo, and severity of hearing loss 2, 3, 6.

Administration and Dosage

  • The dosage and administration of dexamethasone can vary depending on the specific treatment protocol, with some studies using a dose of 5 g/L/d for intratympanic injection 2, 3 and others using a dose of 40 mg daily for systemic therapy 6.
  • The treatment protocol can also involve multiple injections or doses, with some studies using a course of at least 7-day treatment 2, 3.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

[Intratympanic dexamethasone medication for sudden sensorineural hearing loss: clinical evaluation].

Lin chuang er bi yan hou ke za zhi = Journal of clinical otorhinolaryngology, 2006

Research

[The effect of intratympanic dexamethasone or methylprednisolone on treatment of sudden sensorineural hearing loss].

Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery, 2010

Research

Intratympanic Dexamethasone in Sudden Sensorineural Hearing Loss.

Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India, 2022

Research

Intratympanic Triamcinolone or Dexamethasone in Sudden Sensory Neural Hearing Loss: A Randomized Clinical Trial.

Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India, 2023

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.